12:00 AM
 | 
Mar 12, 2007
 |  BioCentury  |  Product Development

Other EPO data

Other EPO data

Study (sponsor) Drug (company) Indication Target Hb
Cochrane meta-analysis 2006 (Cochrane group) Epoetin alfa and beta/ darbepoetin alfa (multiple) Various cancers NA
EPO treatment significantly increased the relative risk of thromboembolic complications vs. control. Evidence was inconclusive for tumor response and overall survival.
Phase II NH19960 study (Roche) CERA/Mircera (Roche) Non-small cell...

Read the full 327 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >